Leanne Munsie
YOU?
Author Swipe
Evaluation of Baseline Diffusion Tensor Imaging Biomarkers in phase 2 multi‐center PROSPECT‐ALZ study Open
Background Diffusion Tensor Imaging (DTI) biomarkers are increasingly utilized in clinical trials of Alzheimer’s disease (AD). They have shown promise in detecting AD related changes in white‐matter (WM) integrity (Raghavan et al., 2020) a…
Assessment of Efficacy and Safety of Zagotenemab Open
This study provides Class II evidence that for patients with early symptomatic AD, zagotenemab does not slow clinical disease progression.
Use of plasma P‐tau217 for enrichment in the Phase 2 PROSPECT‐ALZ study of LY3372689 in early symptomatic Alzheimer’s disease: Cohort selection and baseline characteristics Open
Background Inhibition of O‐linked N‐acetyl glucosaminidase (OGA) is hypothesized to impede the formation of hyperphosphorylated, insoluble tau aggregates and neurofibrillary tangles. LY3372689 is an orally available, potent inhibitor of OG…
Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body Dementia Open
Introduction: PRESENCE was a phase 2 clinical trial assessing the efficacy of mevidalen, a D1 receptor positive allosteric modulator, for symptomatic treatment of Lewy body dementia (LBD). Mevidalen demonstrated improvements in motor and n…
View article: Wrist-worn sensor-based measurements for drug effect detection with small samples in people with Lewy Body Dementia
Wrist-worn sensor-based measurements for drug effect detection with small samples in people with Lewy Body Dementia Open
clinicaltrials.gov, NCT03305809.
Supplementary Material for: Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body Dementia Open
Introduction: PRESENCE was a phase 2 clinical trial assessing the efficacy of mevidalen, a D1 receptor positive allosteric modulator, for symptomatic treatment of Lewy body dementia (LBD). Mevidalen demonstrated improvements in motor and n…
Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia Open
Background: PRESENCE was a Phase 2 trial assessing mevidalen for symptomatic treatment of Lewy body dementia (LBD). Participants received daily doses (10, 30, or 75 mg) of mevidalen (LY3154207) or placebo for 12 weeks. Objective: To evalua…
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial Open
Background Mevidalen is a selective positive allosteric modulator (PAM) of the dopamine D1 receptor subtype. Objective To assess the safety and efficacy of mevidalen for treatment of cognition in patients with Lewy body dementia (LBD). Met…
View article: Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment
Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment Open
Background: Characterizing patients with Parkinson’s disease (PD) and cognitive impairment is important toward understanding their natural history. Objective: Understand clinical, treatment, and cost characteristics of patients with PD pre…
Genome‐wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways Open
Introduction Variability exists in the disease trajectories of Alzheimer's disease (AD) patients. We performed a genome‐wide association study to examine rate of cognitive decline (ROD) in patients with AD. Methods We tested for interactio…
Basic Considerations for the Use of Monoclonal Antibodies in Migraine Open
Background Migraine impacts more than 36 million people in the United States and 1 billion people worldwide. Despite the increasing availability of acute and preventive therapies, there is still tremendous unmet need. Potential treatments …
[P3–476]: IS THE ANNUAL WELLNESS VISIT ADEQUATE TO IMPACT COGNITIVE CARE? Open
One goal of the Medicare Annual Wellness Visit (AWV) is to detect possible cognitive impairment and, if found, facilitate further diagnostic evaluation and care planning. It is unknown if the AWV has an impact on measurable provider-initia…
Supplementary Material for: Calibrating Longitudinal Cognition in Alzheimer's Disease Across Diverse Test Batteries and Datasets Open
Background: We sought to identify optimal approaches by calibrating longitudinal cognitive performance across studies with different neuropsychological batteries. Methods: We examined four approaches to calibrate cognitive performance in n…
Supplementary Material for: Calibrating Longitudinal Cognition in Alzheimer's Disease Across Diverse Test Batteries and Datasets Open
Background: We sought to identify optimal approaches by calibrating longitudinal cognitive performance across studies with different neuropsychological batteries. Methods: We examined four approaches to calibrate cognitive performance in n…
Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia Open
This study aims to confirm the initial pharmacogenetic finding observed within the clinical proof-of-concept trial of an enhanced response to treatment with pomaglumetad methionil (LY2140023 monohydrate) in Caucasian schizophrenia patients…
Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons Open
Our proposed HTR2A and HTR2A-AS1 gene structures dramatically differ from current annotations, now including overlapping exons on the sense and anti-sense strands. We also find orthologous transcript isoforms expressed in mice, providing o…
Additional file 8: Table S4. of Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons Open
Mouse Htr2a exons and coordinates. (XLSX 12Â kb)
Additional file 11: Table S5. of Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons Open
Mouse Htr2a-AS1 exons and coordinates. (XLSX 12Â kb)
Additional file 7: Table S3. of Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons Open
Predicted HTR2A-AS1 transcripts and open reading frames. (XLSX 13Â kb)
Additional file 6: Table S2. of Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons Open
Splice junctions and counts for human HTR2A-AS1. (XLSX 12Â kb)
Additional file 15: Table S1. of Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons Open
Mapping statistics for human DLPFC RNA-Seq samples (XLSX 22Â kb)
Additional file 14: Table S6. of Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons Open
Predicted splicing proteins bound to human HTR2A rs6313 alleles. (XLSX 11Â kb)